Approach Resources, Inc. (AREX) Reaches $3.02 After 7.00% Down Move; Meridian Bioscience, Inc. (VIVO) Had 2 Bullish Analysts

February 15, 2018 - By Richard Conner

The stock of Approach Resources, Inc. (NASDAQ:AREX) is a huge mover today! The stock decreased 4.43% or $0.14 during the last trading session, reaching $3.02. About 125,152 shares traded. Approach Resources, Inc. (NASDAQ:AREX) has risen 23.01% since February 15, 2017 and is uptrending. It has outperformed by 6.31% the S&P500.The move comes after 5 months negative chart setup for the $274.19M company. It was reported on Feb, 15 by Barchart.com. We have $2.81 PT which if reached, will make NASDAQ:AREX worth $19.19 million less.

Among 5 analysts covering Meridian Bioscience (NASDAQ:VIVO), 2 have Buy rating, 1 Sell and 2 Hold. Therefore 40% are positive. Meridian Bioscience had 13 analyst reports since July 28, 2015 according to SRatingsIntel. The stock has “Hold” rating by Canaccord Genuity on Thursday, September 10. The company was maintained on Thursday, January 25 by Piper Jaffray. The firm has “Sell” rating by Piper Jaffray given on Thursday, July 27. The rating was upgraded by Hilliard Lyons to “Buy” on Monday, March 28. Robert W. Baird maintained Meridian Bioscience, Inc. (NASDAQ:VIVO) rating on Thursday, October 19. Robert W. Baird has “Hold” rating and $15.0 target. The stock of Meridian Bioscience, Inc. (NASDAQ:VIVO) has “Sell” rating given on Thursday, October 19 by Piper Jaffray. As per Thursday, January 25, the company rating was maintained by Canaccord Genuity. The firm earned “Sell” rating on Thursday, September 21 by Piper Jaffray. Hilliard Lyons downgraded the stock to “Neutral” rating in Monday, March 21 report. The company was maintained on Thursday, January 25 by Robert W. Baird. See Meridian Bioscience, Inc. (NASDAQ:VIVO) latest ratings:

25/01/2018 Broker: Piper Jaffray Rating: Sell New Target: $11.0 Maintain
25/01/2018 Broker: Canaccord Genuity Rating: Hold New Target: $16.0 Maintain
25/01/2018 Broker: Robert W. Baird Rating: Hold New Target: $16.0 Maintain
19/10/2017 Broker: Robert W. Baird Rating: Hold New Target: $15.0 Maintain
19/10/2017 Broker: Piper Jaffray Rating: Sell New Target: $10.0 Maintain
21/09/2017 Broker: Piper Jaffray Rating: Sell New Target: $9.0 Maintain

Since February 7, 2018, it had 1 insider buy, and 0 selling transactions for $14,750 activity. Shares for $14,750 were bought by Rice John McCune Jr. on Wednesday, February 7.

Investors sentiment increased to 1.37 in Q3 2017. Its up 0.02, from 1.35 in 2017Q2. It increased, as 12 investors sold Meridian Bioscience, Inc. shares while 42 reduced holdings. 24 funds opened positions while 50 raised stakes. 36.26 million shares or 2.14% more from 35.50 million shares in 2017Q2 were reported. Jpmorgan Chase And invested in 1,982 shares or 0% of the stock. The Connecticut-based Aqr Cap Management Ltd Liability has invested 0% in Meridian Bioscience, Inc. (NASDAQ:VIVO). State Of Alaska Department Of Revenue accumulated 8,353 shares. Barrow Hanley Mewhinney & Strauss Lc reported 0% of its portfolio in Meridian Bioscience, Inc. (NASDAQ:VIVO). Sector Pension Board accumulated 26,771 shares or 0% of the stock. Tiaa Cref Investment Mgmt Limited Liability Corporation has invested 0% of its portfolio in Meridian Bioscience, Inc. (NASDAQ:VIVO). California State Teachers Retirement Sys has invested 0% in Meridian Bioscience, Inc. (NASDAQ:VIVO). Teachers Retirement Of The State Of Kentucky has 0% invested in Meridian Bioscience, Inc. (NASDAQ:VIVO). California Pub Employees Retirement System owns 0% invested in Meridian Bioscience, Inc. (NASDAQ:VIVO) for 84,176 shares. Stevens Management Ltd Partnership owns 16,999 shares for 0.01% of their portfolio. Lucus Advisors Ltd Co, New York-based fund reported 24,493 shares. Nine Chapters Capital Mngmt Limited Liability invested in 0.37% or 11,600 shares. 10,200 are held by Keybank Association Oh. Gamco Investors Et Al reported 175,000 shares. Creative Planning holds 0% of its portfolio in Meridian Bioscience, Inc. (NASDAQ:VIVO) for 15,724 shares.

Meridian Bioscience, Inc., a life science company, develops, makes, distributes, and sells diagnostic test kits primarily for various gastrointestinal, viral, respiratory, and parasitic infectious diseases worldwide. The company has market cap of $609.23 million. The firm operates through Diagnostics and Life Science divisions. It has a 28.24 P/E ratio. The Diagnostics segment offers testing platforms and technologies, including isothermal DNA amplification under the illumigene brand; rapid immunoassays, a single-use immunoassays that can be used in point-of-care settings under the TRU, ImmunoCard, and ImmunoCard STAT! brand names; enzyme-linked immunoassays under the Premier brand; and anodic stripping voltammetry, an electrical chemical sensor platform for quantitative determination under the LeadCare brand.

The stock increased 0.35% or $0.05 during the last trading session, reaching $14.4. About 108,165 shares traded. Meridian Bioscience, Inc. (NASDAQ:VIVO) has declined 26.84% since February 15, 2017 and is downtrending. It has underperformed by 43.54% the S&P500.

Among 13 analysts covering Approach Resources (NASDAQ:AREX), 2 have Buy rating, 1 Sell and 10 Hold. Therefore 15% are positive. Approach Resources has $9 highest and $1 lowest target. $3.71’s average target is 22.85% above currents $3.02 stock price. Approach Resources had 24 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Neutral” rating given on Wednesday, September 9 by Macquarie Research. The firm has “Hold” rating by Robert W. Baird given on Tuesday, September 26. Seaport Global downgraded the stock to “Sell” rating in Wednesday, June 21 report. The stock has “Accumulate” rating by KLR Group on Monday, August 10. The rating was maintained by KeyBanc Capital Markets with “Hold” on Monday, November 13. The stock of Approach Resources, Inc. (NASDAQ:AREX) has “Hold” rating given on Wednesday, October 26 by SunTrust. The firm has “Hold” rating given on Tuesday, September 5 by KeyBanc Capital Markets. Wunderlich upgraded Approach Resources, Inc. (NASDAQ:AREX) rating on Wednesday, October 26. Wunderlich has “Buy” rating and $5.50 target. The stock of Approach Resources, Inc. (NASDAQ:AREX) earned “Hold” rating by Wunderlich on Tuesday, May 24. Northland Capital maintained it with “Market Perform” rating and $3 target in Friday, August 7 report.

Approach Resources, Inc., an independent energy company, focuses on the acquisition, exploration, development, and production of unconventional gas and oil reserves in the United States. The company has market cap of $274.19 million. The companyÂ’s properties are primarily located in the Permian Basin in west Texas. It currently has negative earnings. It also owns interests in east Texas Basin.

Investors sentiment decreased to 1.17 in 2017 Q3. Its down 0.33, from 1.5 in 2017Q2. It dropped, as 14 investors sold Approach Resources, Inc. shares while 16 reduced holdings. 14 funds opened positions while 21 raised stakes. 20.88 million shares or 1.85% more from 20.50 million shares in 2017Q2 were reported. New York-based Virtu Fincl Llc has invested 0% in Approach Resources, Inc. (NASDAQ:AREX). Oppenheimer & Inc accumulated 353,150 shares. First Manhattan stated it has 1.40 million shares. Ameritas Investment Partners holds 0% of its portfolio in Approach Resources, Inc. (NASDAQ:AREX) for 3,777 shares. New Generation Advsr Limited Liability reported 3.15% in Approach Resources, Inc. (NASDAQ:AREX). Kornitzer Capital Management Inc Ks has invested 0% of its portfolio in Approach Resources, Inc. (NASDAQ:AREX). Bancorp Of Montreal Can has 0% invested in Approach Resources, Inc. (NASDAQ:AREX). Macquarie Gp owns 7,000 shares. Royal Comml Bank Of Canada has 16,990 shares. Panagora Asset Management Incorporated invested in 0% or 1,303 shares. American Century holds 132,254 shares or 0% of its portfolio. Aqr Mgmt Ltd Liability Corporation stated it has 0% in Approach Resources, Inc. (NASDAQ:AREX). Northern Trust owns 556,759 shares. Goldman Sachs Gp has 547,747 shares for 0% of their portfolio. Nationwide Fund Advsrs invested in 24,367 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: